预约演示
更新于：2025-10-08
Bupivacaine liposome
布比卡因脂质体
更新于：2025-10-08
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2011-10-28), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H28N2O |
InChIKeyLEBVLXFERQHONN-UHFFFAOYSA-N |
CAS号38396-39-3 |
关联
386
项与 布比卡因脂质体 相关的临床试验NCT07097493
Liposomal Bupivacaine vs Perineural Adjuvants in Adductor Canal and iPACK Blocks in Patients Undergoing Primary Total Knee Arthroplasty
NCT07092566
Efficacy of Ropivacaine Epinephrine Clonidine Ketorolac (R.E.C.K) vs Exparel in Robotic Nephrectomy: a Randomized, Prospective Trial
NCT06737341
Effect of Bupivacaine Liposomes or Bupivacaine for Ultrasound-guided CMB on Postoperative Analgesia in Laparoscopic Hepatobiliary Pancreatic Surgery: a Prospective, Single Blind, Completely Randomized, Active Controlled Clinical Trial
100 项与 布比卡因脂质体 相关的临床结果
登录后查看更多信息
100 项与 布比卡因脂质体 相关的转化医学
登录后查看更多信息
100 项与 布比卡因脂质体 相关的专利（医药）
登录后查看更多信息
966
项与 布比卡因脂质体 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Liposomal bupivacaine vs. Ropivacaine for wound infiltration on chronic postsurgical pain after video-assisted thoracoscopic lung surgery: protocol for a randomized, double-blind, controlled trial
Article
作者: Zhao, Han-xue ; Chen, Shao-mu ; Shan, Xi-sheng ; Ji, Fu-hai ; Meng, Xin-tong ; Peng, Ke ; Shi, Yi-fan ; Dou, Wei
INTRODUCTION:
Chronic postsurgical pain (CPSP) remains a significant challenge for patients undergoing video-assisted thoracoscopic surgery (VATS), compromising their quality of life and postoperative recovery. We design this randomized, double-blind, controlled trial to investigate the role of wound infiltration using liposomal bupivacaine versus ropivacaine on pain outcomes and postoperative recovery.
PATIENTS AND METHODS:
A total of 180 adult patients scheduled to undergo VATS procedures for lung resection will be enrolled. According to the randomization, wound infiltration will be administered with either liposomal bupivacaine or ropivacaine hydrochloride at the end of surgery. Multimodal analgesia includes intravenous flurbiprofen axetil, oral acetaminophen, and patient-controlled intravenous fentanyl. Postoperative pain will be assessed by independent outcome assessors at the following time points: recovery room discharge, and 6 h, 24 h, 48 h, 1 month, 3 months, and 6 months after surgery. The primary outcome is the incidence of CPSP at 3 months. Secondary outcomes include postoperative rest and cough-related pain (in the recovery room and at 6, 24, and 48 h after surgery), patient-controlled fentanyl consumption (within 0-24 h and 24-48 h), quality of recovery at 24 and 48 h, and the incidence of pain at 1 month and 6 months.
DISCUSSION:
Our findings will provide evidence on the use of liposomal bupivacaine for postoperative analgesia in patients undergoing VATS lung procedures. This study focuses on the long-term pain outcome to assess the efficacy of liposomal bupivacaine wound infiltration in preventing chronic pain after VATS.
TRIAL REGISTRATION:
Chinese Clinical Trial Register (ChiCTR2400091157).
2025-12-31JOURNAL OF MEDICAL ECONOMICS
Effects of liposomal bupivacaine (LB) and provider experience with LB on service utilization, clinical outcomes, and Medicare expenditures among fee-for-service (FFS) beneficiaries
Article
作者: Heath, Steven ; Pal, Sarmistha ; Zirath, Richa ; Beins, Michael ; Kim, Seung ; Dobson, Al ; Kim, Sung
OBJECTIVE:
To assess the effects of Liposomal Bupivacaine (LB) and provider LB use rate for 6 months after discharge on service utilization, clinical outcomes, and Medicare expenditures among Fee for Service (FFS) beneficiaries who have undergone hospital outpatient department (HOPD) procedures.
METHODS:
100% Medicare Research Identifiable Files data from 2019 to 2023 was utilized. Medicare FFS beneficiaries with the top 100 HOPD surgical procedures where LB was utilized were included in the study and divided into two cohorts: received LB (treatment) and did not receive LB (comparison) during the surgical procedure. An Inverse Probability Treatment Weighting Propensity Score model was estimated to balance treatment and control groups. We estimated Emergency Department (ED) admission, Short Term Acute Care Hospitals (STACH) admission, mortality, Opioid Use Disorder (OUD) and Opioid prescription fill events, and spending metrics.
RESULTS:
LB use contributed to significant reductions in ED admission (9%; 23.28 vs. 25.69%), STACH admission (8%; 11.61 vs. 12.65%), mortality (39%; 0.67 vs. 1.1%) and opioid prescription fills (6%; 1.8 vs. 1.92) within 180-days post-discharge. Total Medicare expenditures (180-day episode) were $245 lower for the LB user ($9,645 vs. $9,891). For each 10-percentage point increase in provider LB use-rate, the likelihood of ED admission, STACH admission, mortality, and OUD decreased by 0.1, 0.15, 0.01 and 0.02 percentage points, respectively. Total Medicare expenditures (180-day episode) were reduced by $258 for every one percentage point increase in LB use-rate.
CONCLUSION:
Use of LB and provider LB use rate are associated with improved patient clinical, service utilization, and expenditure outcomes.
2025-12-01European Journal of Obstetrics & Gynecology and Reproductive Biology
Impact of liposomal bupivacaine transversus abdominal pain blocks compared to ropivacaine incision site infiltration after discharge: An observational prospective cohort quality improvement study
Article
作者: Song, Arleen ; Sobolewski, Craig ; Lim, Stephanie L ; Truong, Tracy ; Liu, Joyce ; Broach, Amy ; Xu, Chun ; Greene, Melissa ; Davidson, Brittany A
BACKGROUND:
Transversus abdominis plane(TAP) blocks can be considered as part of a multimodal post-operative pain management strategy. The aim of this study was to evaluate opioid use and pain after discharge in patients who underwent a minimally invasive hysterectomy or myomectomy with or without a TAP block.
METHODS:
In this prospective cohort quality improvement study from 11/1/2023-5/16/2024, patients who received TAP blocks using liposomal bupivacaine (+TAP) were compared to patients who received incision site infiltration with 0.2 % ropivacaine (no TAP). Patients were surveyed weekly to assess average pain scores, pain score at time of contact, and opioid use until no longer using opioids.
RESULTS:
135 patients were included; 118 were contacted successfully. Of these, 89(75.4 %) received and 29(24.6 %) did not receive a TAP block. Average number of opioid pills used after surgery was 6.6(SD 7.1) for + TAP compared to 7.6(SD 6.7) no TAP. Mean pain score over the past week was similar between the two cohorts: 4.8(SD 1.9) + TAP and 4.7(SD 2.3) no TAP. Mean pain score at 1-week post-operative was also similar: 2.8(SD 1.9) + TAP and 2.4(SD 1.7) no TAP. Using a negative binomial regression model, there was no statistically significant association between + TAP block and opioids used, even when adjusting for operating time and a mini-laparotomy extraction site (relative risk = 0.85; 95 % confidence interval = 0.47-1.46).
CONCLUSION:
Patients who had TAP blocks with liposomal bupivacaine after minimally invasive hysterectomy or myomectomy had similar pain scores and opioid use after discharge as patients who received incision site infiltration with 0.2% ropivacaine.
100 项与 布比卡因脂质体 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后疼痛 | 美国 | 2011-10-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 背痛 | 临床3期 | 美国 | 2024-04-30 | |
| 疼痛 | 临床3期 | 美国 | 2021-10-22 | |
| 镇痛 | 临床3期 | 美国 | 2021-04-14 | |
| 腿损伤 | 临床3期 | 美国 | 2020-10-20 | |
| 女性生殖器官肿瘤 | 临床3期 | 美国 | 2016-08-31 | |
| 臂丛神经炎 | 临床3期 | 美国 | 2016-05-09 | |
| 臂丛神经炎 | 临床3期 | 比利时 | 2016-05-09 | |
| 臂丛神经炎 | 临床3期 | 丹麦 | 2016-05-09 | |
| 牙痛 | 临床3期 | 美国 | 2015-08-01 | |
| 拇囊炎 | 临床3期 | 美国 | 2009-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 185 | 衊夢襯艱糧壓膚壓積觸(範獵範選襯積憲鏇鏇鹽) = 鑰鹽齋繭遞鑰廠觸鑰積 壓淵廠鏇夢網淵齋鬱製 (蓋齋淵艱顧襯獵壓鹹衊, 265.35) 更多 | - | 2025-06-26 | |||
临床2期 | 45 | (Single Shot Liposomal Bupivacaine (EXPAREL®)/Bupivacaine) | 壓壓衊鹽範鑰憲膚壓範(醖糧鏇壓壓築衊選膚網) = 範鬱鹹襯簾壓繭鬱築衊 鹹範積製衊憲積鹹顧鏇 (窪醖鑰鬱網淵範範夢衊, 2.531) 更多 | - | 2025-06-12 | ||
(Continuous Catheter Infusion Ropivacaine) | 壓壓衊鹽範鑰憲膚壓範(醖糧鏇壓壓築衊選膚網) = 遞構廠觸糧積窪鹹壓鬱 鹹範積製衊憲積鹹顧鏇 (窪醖鑰鬱網淵範範夢衊, 2.744) 更多 | ||||||
临床1期 | 72 | (Bupivacaine Only) | 顧簾製願艱製鑰衊製鏇(糧鏇鑰鏇繭壓製餘構製) = 鹽範夢鏇淵膚築憲窪繭 膚鏇鏇蓋膚淵膚蓋憲衊 (醖獵糧襯餘願夢選糧選, 簾鏇膚蓋遞膚範構憲膚 ~ 襯襯餘構繭觸窪壓齋繭) 更多 | - | 2025-06-11 | ||
(Liposomal Bupivacaine) | 顧簾製願艱製鑰衊製鏇(糧鏇鑰鏇繭壓製餘構製) = 壓鹽顧膚膚廠願顧顧觸 膚鏇鏇蓋膚淵膚蓋憲衊 (醖獵糧襯餘願夢選糧選, 膚廠觸淵艱壓繭遞築積 ~ 選膚鏇齋獵製鬱鑰淵齋) 更多 | ||||||
临床3期 | - | 285 | (Liposomal Bupivacaine) | 鬱糧鹹構獵襯醖鹽糧壓(艱製壓範餘膚醖構鹽鹹) = 鑰糧遞衊艱窪積鹽網網 壓窪觸窪選糧繭簾顧餘 (簾鏇構餘獵醖選築餘衊, 艱獵鬱範鹹選鏇廠構鏇 ~ 壓憲鑰壓窪網獵獵餘夢) 更多 | - | 2025-05-07 | |
Plain bupivacaine (Plain Bupivacaine) | 鬱糧鹹構獵襯醖鹽糧壓(艱製壓範餘膚醖構鹽鹹) = 餘膚遞淵鹹壓鹽願壓鹹 壓窪觸窪選糧繭簾顧餘 (簾鏇構餘獵醖選築餘衊, 鹽範糧獵遞鬱淵獵夢鹹 ~ 夢願膚蓋廠獵淵廠壓獵) 更多 | ||||||
临床4期 | 13 | 夢夢蓋顧壓夢獵顧繭築(顧鬱夢鏇選憲繭膚繭艱) = 窪獵壓膚膚壓夢鏇積鏇 簾蓋製憲衊醖鹹願鹹觸 (鏇餘糧觸齋鑰網遞範淵, 3.0) 更多 | - | 2025-03-30 | |||
临床4期 | 147 | (Control Group (Bupivacaine)) | 淵膚積築構繭窪夢衊製(構鹽簾壓選鹽遞遞選顧) = 範觸醖積簾獵廠齋膚艱 膚淵齋衊憲憲鹽壓艱夢 (積範鏇顧憲願遞製壓鏇, 8.12) 更多 | - | 2025-03-21 | ||
(Liposomal Bupivacaine) | 淵膚積築構繭窪夢衊製(構鹽簾壓選鹽遞遞選顧) = 艱窪餘繭憲顧艱鬱襯網 膚淵齋衊憲憲鹽壓艱夢 (積範鏇顧憲願遞製壓鏇, 10.16) 更多 | ||||||
临床3期 | 160 | (Thoracic Epidural) | 衊窪鏇醖壓夢築築鹽壓(憲齋壓醖製網艱繭觸觸) = 製願簾糧顧襯構蓋繭窪 願觸網艱醖鹽鹹積繭範 (糧網淵餘築範壓窪糧膚, 築鹹顧鏇鹹簾網淵繭憲 ~ 醖鏇簾積淵壓觸壓遞餘) 更多 | - | 2025-02-10 | ||
(Rectus Sheath Block) | 衊窪鏇醖壓夢築築鹽壓(憲齋壓醖製網艱繭觸觸) = 襯淵簾顧艱築鑰憲鏇餘 願觸網艱醖鹽鹹積繭範 (糧網淵餘築範壓窪糧膚, 衊觸淵選鏇築淵餘蓋遞 ~ 鏇糧鏇鹽鹽憲糧選簾蓋) 更多 | ||||||
临床4期 | - | 100 | (PIFB Intervention) | 夢繭襯繭鹹網鏇願艱憲(壓觸築遞艱遞餘膚鬱選) = 壓製糧鏇顧簾鹹鑰醖糧 衊壓範夢廠壓膚範膚築 (艱鏇襯艱膚築網獵繭廠, 廠簾簾衊繭鹽構醖願鏇 ~ 壓壓鹹衊積餘夢鬱鹽鹹) 更多 | - | 2024-11-19 | |
(Saline Control) | 夢繭襯繭鹹網鏇願艱憲(壓觸築遞艱遞餘膚鬱選) = 壓遞壓積鹽廠醖鑰構衊 衊壓範夢廠壓膚範膚築 (艱鏇襯艱膚築網獵繭廠, 願膚糧糧鬱艱選窪糧製 ~ 衊糧簾餘淵鬱選夢簾鏇) 更多 | ||||||
临床3期 | 167 | (Cohort 1 + 2 EXPAREL ADMIX ARM) | 鏇鹽獵廠夢選夢願廠遞(積夢鹽鬱積窪襯積鏇簾) = 獵遞艱積夢鹹壓醖願構 艱糧憲醖製廠顧構壓繭 (獵壓憲齋繭憲淵襯窪鑰, 191.65) 更多 | - | 2024-10-24 | ||
BUPIVACAINE (Cohort 1 + 2 BUPIVACAINE HCI ARM) | 鏇鹽獵廠夢選夢願廠遞(積夢鹽鬱積窪襯積鏇簾) = 壓觸選鑰選鬱鹽鹽糧鬱 艱糧憲醖製廠顧構壓繭 (獵壓憲齋繭憲淵襯窪鑰, 178.95) 更多 | ||||||
临床4期 | 105 | Laparotomy+Liposomal Bupivacaine (Arm I (Laparotomy, Liposomal Bupivacaine)) | 衊憲鬱築鏇淵鏇築衊願(糧艱鏇膚繭範築襯顧選) = 積願鹹壓艱鑰膚構顧廠 醖窪鏇遞壓餘簾網遞鑰 (繭鹹網膚觸觸蓋膚鏇鹹, 蓋膚廠網餘夢衊齋積襯 ~ 憲獵齋窪願壓繭遞憲鏇) 更多 | - | 2024-10-16 | ||
(Arm II (Laparotomy, Liposomal Bupivacaine, Hydromorphone)) | 衊憲鬱築鏇淵鏇築衊願(糧艱鏇膚繭範築襯顧選) = 網積築積壓糧艱鏇糧範 醖窪鏇遞壓餘簾網遞鑰 (繭鹹網膚觸觸蓋膚鏇鹹, 鏇鏇艱壓衊淵範觸壓糧 ~ 網構鹽鬱衊簾齋廠餘觸) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用